Q-omics provides the consensus-scored ENKD1 profile across patient tissues and cancer cell-line models. ENKD1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ENKD1 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, ENKD1 RNA expression shows 15,776 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UVM, COAD, and KIRP as cancer lineages where ENKD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ENKD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ENKD1 survival associations across molecular data types. ENKD1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ENKD1 RNA expression–survival associations across cancer types. High ENKD1 expression shows unfavorable associations in COAD, LGG and LIHC, but favorable associations in UVM, UCEC and KIRP. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ENKD1 RNA expression.
This table summarizes ENKD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ENKD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ENKD1 shows lower tumor expression in THCA, KICH and LUSC and higher tumor expression in COAD, KIRC and KIRP. The COAD box plot shows higher ENKD1 RNA expression in tumor versus normal tissue (log2 FC = +1.182, t-test p < 0.001).
This table shows molecular features associated with ENKD1 in patient tissues and cancer cell lines. In patient samples, ENKD1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ENKD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and SOFT_TISSUE.
